Addressing overdiagnosis and overtreatment in cancer

A prescription for change

Laura J. Esserman, Ian M. Thompson, Brian Reid, Peter Nelson, David F. Ransohoff, H. Gilbert Welch, Shelley Hwang, Donald A. Berry, Kenneth W Kinzler, William C. Black, Mina Bissell, Howard Parnes, Sudhir Srivastava

Research output: Contribution to journalArticle

Abstract

A vast range of disorders-from indolent to fast-growing lesions-are labelled as cancer. Therefore, we believe that several changes should be made to the approach to cancer screening and care, such as use of new terminology for indolent and precancerous disorders. We propose the term indolent lesion of epithelial origin, or IDLE, for those lesions (currently labelled as cancers) and their precursors that are unlikely to cause harm if they are left untreated. Furthermore, precursors of cancer or high-risk disorders should not have the term cancer in them. The rationale for this change in approach is that indolent lesions with low malignant potential are common, and screening brings indolent lesions and their precursors to clinical attention, which leads to overdiagnosis and, if unrecognised, possible overtreatment. To minimise that potential, new strategies should be adopted to better define and manage IDLEs. Screening guidelines should be revised to lower the chance of detection of minimal-risk IDLEs and inconsequential cancers with the same energy traditionally used to increase the sensitivity of screening tests. Changing the terminology for some of the lesions currently referred to as cancer will allow physicians to shift medicolegal notions and perceived risk to reflect the evolving understanding of biology, be more judicious about when a biopsy should be done, and organise studies and registries that offer observation or less invasive approaches for indolent disease. Emphasis on avoidance of harm while assuring benefit will improve screening and treatment of patients and will be equally effective in the prevention of death from cancer.

Original languageEnglish (US)
JournalThe Lancet Oncology
Volume15
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Prescriptions
Neoplasms
Terminology
Medical Overuse
Early Detection of Cancer
Registries
Observation
Guidelines
Physicians
Biopsy

ASJC Scopus subject areas

  • Oncology

Cite this

Esserman, L. J., Thompson, I. M., Reid, B., Nelson, P., Ransohoff, D. F., Welch, H. G., ... Srivastava, S. (2014). Addressing overdiagnosis and overtreatment in cancer: A prescription for change. The Lancet Oncology, 15(6). https://doi.org/10.1016/S1470-2045(13)70598-9

Addressing overdiagnosis and overtreatment in cancer : A prescription for change. / Esserman, Laura J.; Thompson, Ian M.; Reid, Brian; Nelson, Peter; Ransohoff, David F.; Welch, H. Gilbert; Hwang, Shelley; Berry, Donald A.; Kinzler, Kenneth W; Black, William C.; Bissell, Mina; Parnes, Howard; Srivastava, Sudhir.

In: The Lancet Oncology, Vol. 15, No. 6, 2014.

Research output: Contribution to journalArticle

Esserman, LJ, Thompson, IM, Reid, B, Nelson, P, Ransohoff, DF, Welch, HG, Hwang, S, Berry, DA, Kinzler, KW, Black, WC, Bissell, M, Parnes, H & Srivastava, S 2014, 'Addressing overdiagnosis and overtreatment in cancer: A prescription for change', The Lancet Oncology, vol. 15, no. 6. https://doi.org/10.1016/S1470-2045(13)70598-9
Esserman, Laura J. ; Thompson, Ian M. ; Reid, Brian ; Nelson, Peter ; Ransohoff, David F. ; Welch, H. Gilbert ; Hwang, Shelley ; Berry, Donald A. ; Kinzler, Kenneth W ; Black, William C. ; Bissell, Mina ; Parnes, Howard ; Srivastava, Sudhir. / Addressing overdiagnosis and overtreatment in cancer : A prescription for change. In: The Lancet Oncology. 2014 ; Vol. 15, No. 6.
@article{808a0c1c111c41e894b20c583f3abba5,
title = "Addressing overdiagnosis and overtreatment in cancer: A prescription for change",
abstract = "A vast range of disorders-from indolent to fast-growing lesions-are labelled as cancer. Therefore, we believe that several changes should be made to the approach to cancer screening and care, such as use of new terminology for indolent and precancerous disorders. We propose the term indolent lesion of epithelial origin, or IDLE, for those lesions (currently labelled as cancers) and their precursors that are unlikely to cause harm if they are left untreated. Furthermore, precursors of cancer or high-risk disorders should not have the term cancer in them. The rationale for this change in approach is that indolent lesions with low malignant potential are common, and screening brings indolent lesions and their precursors to clinical attention, which leads to overdiagnosis and, if unrecognised, possible overtreatment. To minimise that potential, new strategies should be adopted to better define and manage IDLEs. Screening guidelines should be revised to lower the chance of detection of minimal-risk IDLEs and inconsequential cancers with the same energy traditionally used to increase the sensitivity of screening tests. Changing the terminology for some of the lesions currently referred to as cancer will allow physicians to shift medicolegal notions and perceived risk to reflect the evolving understanding of biology, be more judicious about when a biopsy should be done, and organise studies and registries that offer observation or less invasive approaches for indolent disease. Emphasis on avoidance of harm while assuring benefit will improve screening and treatment of patients and will be equally effective in the prevention of death from cancer.",
author = "Esserman, {Laura J.} and Thompson, {Ian M.} and Brian Reid and Peter Nelson and Ransohoff, {David F.} and Welch, {H. Gilbert} and Shelley Hwang and Berry, {Donald A.} and Kinzler, {Kenneth W} and Black, {William C.} and Mina Bissell and Howard Parnes and Sudhir Srivastava",
year = "2014",
doi = "10.1016/S1470-2045(13)70598-9",
language = "English (US)",
volume = "15",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "6",

}

TY - JOUR

T1 - Addressing overdiagnosis and overtreatment in cancer

T2 - A prescription for change

AU - Esserman, Laura J.

AU - Thompson, Ian M.

AU - Reid, Brian

AU - Nelson, Peter

AU - Ransohoff, David F.

AU - Welch, H. Gilbert

AU - Hwang, Shelley

AU - Berry, Donald A.

AU - Kinzler, Kenneth W

AU - Black, William C.

AU - Bissell, Mina

AU - Parnes, Howard

AU - Srivastava, Sudhir

PY - 2014

Y1 - 2014

N2 - A vast range of disorders-from indolent to fast-growing lesions-are labelled as cancer. Therefore, we believe that several changes should be made to the approach to cancer screening and care, such as use of new terminology for indolent and precancerous disorders. We propose the term indolent lesion of epithelial origin, or IDLE, for those lesions (currently labelled as cancers) and their precursors that are unlikely to cause harm if they are left untreated. Furthermore, precursors of cancer or high-risk disorders should not have the term cancer in them. The rationale for this change in approach is that indolent lesions with low malignant potential are common, and screening brings indolent lesions and their precursors to clinical attention, which leads to overdiagnosis and, if unrecognised, possible overtreatment. To minimise that potential, new strategies should be adopted to better define and manage IDLEs. Screening guidelines should be revised to lower the chance of detection of minimal-risk IDLEs and inconsequential cancers with the same energy traditionally used to increase the sensitivity of screening tests. Changing the terminology for some of the lesions currently referred to as cancer will allow physicians to shift medicolegal notions and perceived risk to reflect the evolving understanding of biology, be more judicious about when a biopsy should be done, and organise studies and registries that offer observation or less invasive approaches for indolent disease. Emphasis on avoidance of harm while assuring benefit will improve screening and treatment of patients and will be equally effective in the prevention of death from cancer.

AB - A vast range of disorders-from indolent to fast-growing lesions-are labelled as cancer. Therefore, we believe that several changes should be made to the approach to cancer screening and care, such as use of new terminology for indolent and precancerous disorders. We propose the term indolent lesion of epithelial origin, or IDLE, for those lesions (currently labelled as cancers) and their precursors that are unlikely to cause harm if they are left untreated. Furthermore, precursors of cancer or high-risk disorders should not have the term cancer in them. The rationale for this change in approach is that indolent lesions with low malignant potential are common, and screening brings indolent lesions and their precursors to clinical attention, which leads to overdiagnosis and, if unrecognised, possible overtreatment. To minimise that potential, new strategies should be adopted to better define and manage IDLEs. Screening guidelines should be revised to lower the chance of detection of minimal-risk IDLEs and inconsequential cancers with the same energy traditionally used to increase the sensitivity of screening tests. Changing the terminology for some of the lesions currently referred to as cancer will allow physicians to shift medicolegal notions and perceived risk to reflect the evolving understanding of biology, be more judicious about when a biopsy should be done, and organise studies and registries that offer observation or less invasive approaches for indolent disease. Emphasis on avoidance of harm while assuring benefit will improve screening and treatment of patients and will be equally effective in the prevention of death from cancer.

UR - http://www.scopus.com/inward/record.url?scp=84899752622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899752622&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(13)70598-9

DO - 10.1016/S1470-2045(13)70598-9

M3 - Article

VL - 15

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 6

ER -